VistaGen Therapeutics (VSTA) Goes Beyond Drug Testing

VistaGen is known best for its proprietary stem cell technology used in their novel bioassay systems to provide superior toxicity testing of new drug candidates. The company’s Human Clinical Trials in a Test TubeTM platform is designed to provide accurate and early prediction of potential heart and liver toxicity issues for new drugs, allowing pharmaceutical companies to avoid spending billions of dollars bringing a potentially unsafe drug to market. In particular, VistaGen’s CardioSafe 3D bioassay system is focused on assessing in vivo cardiac effects of new drug candidates.

The company is also developing AV-101, a unique prodrug candidate for the treatment of neuropathic pain, a serious and chronic condition affecting approximately 1.8 million people in the U.S. alone. The drug’s strength is its remarkable ability to rapidly and efficiently transport across the blood-brain barrier, where it can convert into an effective blocker at the site of seizures and neural damage in the brain and spinal cord. AV-101 is currently in Phase 1b development in the U.S. VistaGen believes that the safety studies completed in its Phase 1 clinical program may also enable Phase 2 development of AV-101 for depression, epilepsy, and Parkinson’s disease.

For additional information, visit the company’s website at www.VistaGen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html